Neovacs reports full-year 2018 Financial results and provides corporate update

RESS RELEASE ·  PRESS RELEASE  · PRESS RELEASE NEOVACS REPORTS FULL-YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE KEY OPINION LEADERS VALIDATE THE THERAPEUTIC POTENTIAL OF IFNa KINOID IN  LUPUS TREATMENT FOLLOWING THE RESULTS OF THE PHASE IIB CLINICAL STUDY   SUCCESSFUL IN VIVO PROOF OF CONCEPT  FOR ITS IL-4 / IL-13 KINOID A NEW THERAPEUTIC VACCINE  TO TREAT MITE-INDUCED ASTHMA   PATENT REGISTERED IN EUROPE AND THE U.S. FOR IL-4 / IL-13 KINOID, CANDIDATE   VACCINE IN THE TREATMENT OF ALLERGIES   FINANCIAL VISIBILITY BEYOND 12 MONTHS   NET LOSS REDUCTION BY € 4M Paris, March 25, 2019, 7:30 am ...

Gepostet in der Kategorie Wirtschaft (Anzahl der ansichten:) 2

Ähnlich Nachrichten